ArticleNephrology (Carlton, Vic.)2025
Burden of Valvular Heart Disease Diagnosed on Protocolised Echocardiography for Waitlist Placement in End-Stage Kidney Patients.
Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Torque teno virus viral load and hospitalisation for infections in long-term kidney transplant recipients: a single-centre prospective cohort study.BMC nephrology · 2026Article
- Burden of Valvular Heart Disease Diagnosed on Protocolised Echocardiography for Waitlist Placement in End-Stage Kidney Patients.Nephrology (Carlton, Vic.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe burden of valvular heart disease (VHD), which is high amongst end-stage kidney disease patients (ESKD), is less well defined in those referred to the transplant waitlist. We aimed to determine the prevalence, incidence, impact on survival and risk factors of VHD in ESKD patients who are referred for deceased donor kidney transplant (DDKT).
methodsThis is a single-centre retrospective cohort analysis of ESKD patients who were referred for waitlist placement between 2009 and 2017 and underwent at least 1 transthoracic echocardiogram (TTE), then followed up until death or transplantation. Significant VHD was defined as VHD that was moderate or worse in severity as assessed on echocardiography.
resultsOf the 512 patients included, 89 (17.4%) had significant baseline VHD. Over a median follow-up of 6.6 years, severe VHD (adjusted HR (aHR) 2.73, 95% CI 1.28-5.83, p = 0.009), severe tricuspid regurgitation (aHR 3.04, 95% CI 1.20-7.69, p = 0.02), significant aortic stenosis (aHR 2.93, 95% CI 1.15-7.45, p = 0.02), MS (aHR 3.83, 95% CI 1.54-9.50, p = 0.004) and AR (aHR 1.76, 95% CI 1.05-2.97, p = 0.03) were independently associated with all-cause mortality. In 350 patients with repeat TTEs, 53 (15.1%) developed de novo significant VHD or progression of pre-existing VHD, which was independently associated with all-cause mortality (aHR 2.02, 95% CI 1.14-3.61, p = 0.02). Age, time on dialysis, and mineral bone disease were associated with baseline VHD and de novo or progression of pre-existing VHD.
conclusionVHD is common amongst ESKD patients referred for DDKT waitlist. Both baseline and progressive VHD predict worse survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.